A Multicenter, Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Hospitalized Patients With Severe COVID-19
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Upanovimab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Sinocelltech
Most Recent Events
- 13 Mar 2025 Status changed from recruiting to discontinued.
- 07 Apr 2021 Planned End Date changed from 10 Oct 2021 to 27 Dec 2021.
- 07 Apr 2021 Planned primary completion date changed from 10 May 2021 to 27 Jun 2021.